DCP
PCRX icon

DSM Capital Partners’s Pacira BioSciences PCRX Stock Holding History

DSM Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-20,965
Closed -$2.03M – 61
2014
Q3 		$2.03M Sell
20,965
-340
-2% -$33.1K 0.04% 41
2014
Q2 		$1.96M Buy
+21,305
New +$1.62M 0.04% 37

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DSM Capital Partners's PCRX Position: Q4 2014 in Review

DSM Capital Partners sold out of Pacira BioSciences (PCRX) in Q4 2014, closing a stake of 20,965 shares — an estimated $2.03M sold.

DSM Capital Partners first reported a position in PCRX in Q2 2014 and held it in 2 quarters. The position peaked at $2.03M in Q3 2014. 200 funds tracked by Wall St. Rank hold PCRX as of Q4 2014.

  • DSM Capital Partners reported no remaining Pacira BioSciences position as of Q4 2014 after selling out during the quarter.
  • DSM Capital Partners sold 20,965 Pacira BioSciences shares in Q4 2014, an estimated $2.03M.
  • DSM Capital Partners first reported a position in Pacira BioSciences in Q2 2014 and held it in 2 quarters.
  • DSM Capital Partners's Pacira BioSciences position peaked at $2.03M in Q3 2014.
  • 200 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2014.

Based on DSM Capital Partners's 13F filing for Q4 2014, filed 12 Feb 2015.